Sugi Predict

Sugi Predict / Compounds / SCHEMBL79456

SCHEMBL79456

SCHEMBL79456

COc1ccc(/C=C/C(=O)O)c(OC)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.79
▸ ALDH1A1 P00352 3/20 0.79
▸ MEN1 O00255 3/20 0.79
▸ KMT2A Q03164 3/20 0.79
▸ NPC1 O15118 2/20 0.71
▸ RAB9A P51151 2/20 0.71
▸ SMN1; SMN2 Q16637 1/20 0.71
▸ TNFRSF1A P19438 1/20 0.70
▸ CYP1A1 P04798 5/20 0.68
▸ CYP1A2 P05177 5/20 0.68
▸ CYP1B1 Q16678 4/20 0.68
▸ LY96 Q9Y6Y9 1/20 0.67
▸ MAPK1 P28482 2/20 0.65
▸ HPGD P15428 2/20 0.63
▸ LMNA P02545 1/20 0.63
▸ CHRNA7 P36544 1/20 0.62
▸ GAA P10253 1/20 0.61
▸ BACE1 P56817 1/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ TP53 P04637 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29449851 1.00 MAPT (0.79) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL79457 1.00 MAPT (0.79) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL27892982 1.00 MAPT (0.79) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL27858760 0.98 MAPT (0.77) MAPTALDH1A1MEN1KMT2ANPC1
Hydrochloric Acid SCHEMBL15299858 0.98 MAPT (0.77) MAPTALDH1A1MEN1KMT2ANPC1
Cinnamic Acid SCHEMBL16271170 0.91 CYP1A1 (0.71) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL10468808 0.91 MAPT (0.85) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL10468807 0.91 MAPT (0.85) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL10661702 0.90 MAPT (0.69) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL6782178 0.90 MAPT (0.69) MAPTALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497636-B2 Recombinant Saccharomyces cerevisiae cells for cannabinoid production NATIONAL UNIVERSITY OF SINGAPORE (SG) 2025-12-16 — — US claimed
CN-113024573-A Epodophyllotoxin derivative, preparation method and application thereof in preparation of antitumor drugs 江苏百奥信康医药科技有限公司 2021-06-25 — — CN claimed
CN-102887882-B Synthesis method of precocene and analogs thereof LIU ZHONGQUAN 2014-12-10 — — CN claimed
CN-102887882-A Synthesis method of precocene and analogs thereof LIU ZHONGQUAN 2013-01-23 — — CN claimed
EP-2323502-B1 FLAVAN-3-OL CONTAINING FOODSTUFFS UNILEVER PLC (GB) 2012-09-05 — — EP claimed
EP-2323502-A1 FLAVAN-3-OL CONTAINING FOODSTUFFS Unilever PLC (GB) 2011-05-25 — — EP claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
US-20100062131-A1 FLAVAN-3-OL CONTAINING FOODSTUFFS CONOPCO, INC., D/B/A UNILEVER (US) 2010-03-11 — — US claimed
WO-2010026003-A1 FLAVAN-3-OL CONTAINING FOODSTUFFS UNILEVER PLC (GB) 2010-03-11 — — WO claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-20060000778-A1 high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers MCMASTER UNIVERSITY (CA) 2006-01-05 — — US claimed
WO-2005102503-A1 PERVAPORATION COMPOSITE MEMBRANES MCMASTER UNIVERSITY (CA) 2005-11-03 — — WO claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
EP-0491706-B1 METHOD OF PREPARING A SAMPLE FOR ANALYSIS FINNIGAN MAT LTD (GB) 1995-09-06 — — EP claimed
EP-0491706-A1 METHOD OF PREPARING A SAMPLE FOR ANALYSIS. FINNIGAN MAT LTD (GB) 1992-07-01 — — EP claimed
WO-1991004570-A1 METHOD OF PREPARING A SAMPLE FOR ANALYSIS FINNIGAN MAT LTD. (GB) 1991-04-04 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 MAPT 4074/4885ALDH1A1 1569/4885MEN1 685/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 MAPT 539/4885ALDH1A1 1723/4885MEN1 1466/4885
US-20100062131-A1 FLAVAN-3-OL CONTAINING FOODSTUFFS TAS2R50, TAS2R3, TAS1R3 MAPT 4038/4885ALDH1A1 650/4885MEN1 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.